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Diabetes is associated with severe secondary complications,
largely caused by poor glycemic control. Treatment with exog-
enous insulin fails to prevent these complications completely,
leading to signiﬁcant morbidity and mortality. We previously
demonstrated that it is possible to generate a “glucose sensor” in
skeletal muscle through coexpression of glucokinase and insulin,
increasing glucose uptake and correcting hyperglycemia in diabetic
mice. Here, we demonstrate long-term efﬁcacy of this approach
in a large animal model of diabetes. A one-time intramuscular
administration of adeno-associated viral vectors of serotype 1
encoding for glucokinase and insulin in diabetic dogs resulted
in normalization of fasting glycemia, accelerated disposal of glu-
cose after oral challenge, and no episodes of hypoglycemia dur-
ing exercise for .4 years after gene transfer. This was associated
with recovery of body weight, reduced glycosylated plasma pro-
teins levels, and long-term survival without secondary complica-
tions. Conversely, exogenous insulin or gene transfer for insulin
or glucokinase alone failed to achieve complete correction of
diabetes, indicating that the synergistic action of insulin and glu-
cokinase is needed for full therapeutic effect. This study provides
the ﬁrst proof-of-concept in a large animal model for a gene trans-
fer approach to treat diabetes. Diabetes 62:1718–1729, 2013
Diabetes is a chronic disease for which there iscurrently no cure. Patients with type 1 diabetesneed insulin replacement therapy to survive,but glycemia is not always properly regulated.
Chronic hyperglycemia leads to development of diabetes-
associated microvascular, macrovascular, and neurologic
complications, which can be delayed by intensive insulin
therapy (1). However, this treatment is not suitable for all
diabetic patients because of its high risk of hypoglycemia
secondary to excessive insulin dosage (1). Thus, precise
regulation of glucose homeostasis is a major challenge in
diabetes management. Therapeutic beneﬁt has been ob-
tained with islet transplantation (2), but access to human
islets and the necessary immunosuppressive therapy are
important limitations. Alternative cell- and gene-based
therapies, centered around the engineering of nonpan-
creatic tissues to produce insulin, or the generation of
stem cell-derived b cells, are undergoing investigation
(3,4); however, long-term safety and efﬁcacy data in large
animal models are lacking.
Genetic engineering of skeletal muscle to counteract
hyperglycemia is an attractive strategy to correct diabetes.
Skeletal muscle is responsible for the disposal of ;70% of
circulating glucose after a meal. In muscle, glucose utili-
zation is controlled by insulin-stimulated glucose transport
through the glucose transporter type 4 (GLUT4) (5) and
phosphorylation by hexokinase II, which has a low Km for
glucose and is inhibited by glucose-6-phosphate, limiting
glucose uptake (6). In diabetic muscle, because of the lack
of insulin, GLUT4 translocation to the plasma membrane
and hexokinase II activity both decrease. In contrast
to hexokinase II, the liver enzyme glucokinase has a high
Km for glucose, is not inhibited by glucose-6-phosphate,
and shows kinetic cooperation with glucose (7). When
expressed in skeletal muscle of transgenic mice, glucoki-
nase facilitates glucose uptake only when blood glucose is
high (8). However, during diabetes, constant basal levels
of insulin are required to ensure the presence of GLUT4 on
the cell membrane (5). These observations led to the hy-
pothesis that regulation of glycemia could be achieved by
coexpression in skeletal muscle of glucokinase and low
levels of insulin; in such a system, glucose inﬂux is regu-
lated by circulating glucose levels allowing glucose uptake
only when hyperglycemia is present. Accordingly, intra-
muscular delivery of adeno-associated viral (AAV) vectors
expressing insulin and glucokinase to diabetic mice re-
sulted in disease correction (9).
AAV vectors are the vector of choice for in vivo gene
therapy because of their excellent safety and efﬁcacy
proﬁles. Preclinical studies have shown that AAV-mediated
gene transfer results in long-term gene expression in small
and large animal models (10). Recently, these preclinical
data have been successfully translated into humans
(11,12). In the most clear-cut examples of success, clinical
studies of hemophilia B (12) and Leber congenital amau-
rosis (11) were preceded by convincing studies of efﬁcacy
in large animal models (13,14). However, for most proof-
of-concept studies in mice, no successful scale-up or long-
term efﬁcacy has been reported. This goal has yet to be
demonstrated in large animal models of diabetes with gene
and cell therapy approaches. Here, we used dogs treated
with b-cell cytotoxic drugs as a model of experimental
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diabetes (15), because large animal models of autoimmune
diabetes are not available. We demonstrate that after
a single intramuscular injection of AAV1 vectors, insulin
transgene (Ins) and glucokinase (Gck) transgene act syn-
ergistically to achieve tight control of glycemia. This rep-
resents the ﬁrst proof-of-concept study of long-term
correction of diabetes in a large animal model using gene
transfer.
RESEARCH DESIGN AND METHODS
Animals. Male Beagle dogs were purchased from Isoquimen (Barcelona,
Spain) and housed at Servei de Granges i Camps Experimentals of the Uni-
versitat Autònoma de Barcelona. Animals were fed individually once daily at
9:00 A.M. with 30 g/kg body weight of standard dry food (Nestle, Vevey, Swit-
zerland) or twice daily at 9:00 A.M. and 9:00 P.M. with 15 g/kg body weight of
diabetic food (Prescription Diets w/d; Hills, Topeka, KS) when indicated. Dogs
were monitored regularly at the Universitat Autònoma de Barcelona Veteri-
nary Clinical Hospital. C56Bl6 male mice (Harlan Teklad, Barcelona, Spain)
were fed ad libitum with a standard diet (Harlan Teklad) and maintained in the
speciﬁc pathogen free (SPF) mouse facility at the Center of Animal Biotech-
nology and Gene Therapy under a 12-h light–dark cycle (lights on at 8:00 A.M.).
The Ethics Committee on Animal and Human Experimentation approved all
procedures.
Diabetes induction. Experimental diabetes was induced in 6- to 12-month-old
dogs by a single intravenous injection of a mixture of streptozotocin (35 mg/kg)
and alloxan (40 mg/kg) (Sigma, St. Louis, MO) as described previously (15).
When hyperglycemia developed, dogs were maintained without exogenous
insulin treatment, unless indicated. Dogs receiving exogenous insulin were
injected subcutaneously with Lantus (Sanoﬁ-Aventis, Paris, France). When
indicated, exogenous insulin treatment was optimized individually, increasing
gradually the insulin dose up to the maximum tolerated dose that did not
cause hypoglycemia. To induce diabetes in mice, animals aged 8 weeks were
administered, for 5 consecutive days, an intraperitoneal injection of strepto-
zotocin (45 mg/kg body weight) dissolved in 0.1 mol/L citrate buffer (pH 4.5)
immediately before administration.
AAV production and administration. AAV vectors were produced by triple
transfection of HEK293 cells and puriﬁed by a CsCl-based gradient method (16).
Expression of an engineered human insulin gene containing an endoprotease
furin cleavage signal and expression of rat glucokinase were driven by the
cytomegalovirus (CMV) promoter in both vectors (9). For certain experiments
as indicated, codon-optimized versions of human insulin (oIns; with furin
cleavage sites) and human glucokinase cDNAs (oGck) were used. Vectors
were delivered to a total of 12–25 sites on the lateral aspect of the thigh (with
a ﬁve-prong needle syringe) and the craneolateral face of the leg (single point
injections) of both hind limbs, with maximal vector dose per site of injection
being,63 1011 vg (Supplementary Fig. 1). Dogs received a vector dose of 13
1012 vg/kg or 2 3 1012 vg/kg 2–4 weeks after diabetes induction (Supple-
mentary Table 1). Mice were intramuscularly treated with 4 3 1012 vg/kg of
AAV1-oGck 2 weeks after diabetes induction, distributed into tibialis cranealis,
gastrocnemius, and quadriceps muscles of both hindlimbs.
Biodistribution. Total DNA was isolated from Dog3 with MasterPureDNA
Puriﬁcation Kit (Epicentre Biotechnologies, Madison, WI). Vector genome
copy number was determined in 20 ng of genomic DNA by TaqMan quan-
titative PCR with primers and probe speciﬁc for the cytomegalovirus (CMV)
promoter: forward primer, 59-CACCAATGGGCGTGGATAGC-39; reverse primer,
59GCAGTTGTTACGACATTTTGGAAA-39; and probe, 59-ATTTCCAAGTCTC
CACCC-39.
RNA analysis. Liver and quadriceps total RNA was extracted (Qiagen,
Valencia, CA) from dog and mouse samples and analyzed by Northern blot with
radiolabeled (GE Healthcare UK, Buckinghamshire, UK) insulin or glucokinase
cDNA probes or by quantitative RT-PCR for detection of glucokinase regulatory
protein: forward primer, CAAGCACCAAGCGGTATCA; and reverse primer,
GTCAGTGGGTTGGACTTCTCT.
Western blotting. Nuclear and cytoplasmatic protein fractions were
obtained from skeletal muscle and liver extracted from starved mice, or 15
min after intraperitoneal glucose injection (3 g/kg body weight) as described
(17). Fractioned or total protein lysates were subjected to SDS-PAGE,
electrotransferred on polyvinylidene ﬂuoride (Millipore) membranes, and
probed with Akt (Cell Signaling, Danvers, MA), pAkt (Cell Signaling), Gck
(Sigma), Histone 3 (Abcam, Cambridge, UK), and a-tubulin (Abcam) as
previously described (18). All rabbit primary antibodies were immunode-
tected using horseradish peroxidase–conjugated polyclonal swine anti-rabbit
immunoglobulins (Dako, Glostrup, Denmark). Loading was normalized by
a-tubulin.
Morphological and immunohistochemical analysis. Dog samples were
ﬁxed in 10% formalin, embedded in parafﬁn, and sectioned. Double glucagon
and insulin immunostaining was performed with mouse antiglucagon (Sigma)
and guinea pig anti-insulin (Sigma) antibodies. Biotinylated horse anti-mouse
(Vector Laboratories, Burlingame, CA) followed by streptavidin-conjugated
Alexa488 (Molecular Probes, Leiden, the Netherlands) and Alexa568-conjugated
goat anti-guinea pig (Molecular Probes) were used as secondary antibodies.
The b-cell area was measured on four sections of pancreas biopsy samples,
or multiple areas from the whole pancreas in necropsy samples, stained with
anti-insulin and horseradish peroxidase–conjugated rabbit anti-guinea pig
immunoglobulin (Dako, Glostrup, Denmark). Pancreatic b-cell area was cal-
culated by dividing the area of insulin-positive cells by total pancreatic area
of each section. To analyze muscle integrity, cross-sections were stained
with hematoxylin and eosin or rabbit antilaminin (Dako, Glostrup, Denmark).
Periodic acid-Schiff staining was used to evaluate muscle glycogen content
(Sigma).
Hormone and metabolite determinations. Serum insulin was measured
with human insulin radioimmunoassay (Millipore, Billerica, MA). Serum human
C-peptide was determined with C-peptide radioimmunoassay (Millipore) that
does not cross-react with insulin or with canine C-peptide. Serum glucagon was
measured by radioimmunoassay (Millipore). Blood glucose levels were de-
termined using a Glucometer Elite analyzer (Bayer, Leverkusen, Germany).
Serum fructosamine concentration was measured by nitroblue tetrazolium
reduction test. The concentration of glycogen in skeletal muscle was measured
as previously described (9). Urine was analyzed by Multistix 10 SG Urinalysis
Strips (Siemens, Munich, Germany).
Oral glucose tolerance test. Oral glucose tolerance tests (OGTTs) were
performed in either 12- or 24-h fasted dogs. Brieﬂy, animals were administered
an oral gavage of glucose 1.75 g/kg body weight. Glycemia was determined at
times 0, 15, and 30 min, and then every half hour up to 3 h after glucose ad-
ministration.
Exercise test. Fasted dogs (24 h) were subjected to 37 min of exercise under
increasing speed and slope on a variable speed belt treadmill (Starker Hund
S.A.S., Padua, Italy). The protocol was as follows: 1) 5 min, 0 degrees, 4 km/h; 2)
5min, 0 degrees, 8 km/h; 3) 5min, 2.5 degrees, 8 km/h; 4) 5min, 5 degrees, 8 km/h;
5) 5 min, 7.5 degrees, 8 km/h; 6) 5 min, 10 degrees, 8 km/h; 7) 5 min, 0 degrees, 10
km/h; and 8) 2min, 0 degrees, 4 km/h. Dogswere allowed a recovery time equal to
the exercise period (Video 1).
Glucokinase activity determination. To measure glucokinase activity in
skeletal muscle, tissue biopsy samples were obtained from mice or from
necropsy samples from Dog3. Frozen mouse gastrocnemius or dog quadriceps
samples were homogenized in an ice-cold buffer (pH 7.4) containing 100 mmol/L
Gly-Gly, 200 mmol/L ClK, 5 mmol/L DTT, and 65 mmol/L Tris. Samples were
then centrifuged to pellet insoluble material. The glucose phosphorylation
capacity was assayed in the supernatants at 30°C in a buffer containing 50
mmol/L Gly-Gly, 100 mmol/L KCl, 2.5 mmol/L DTT, glucose-6-phosphate de-
hydrogenase (1 units/mL), 0.5 mmol/L NADP, and 4.5 mmol/L ATP-Mg. Glu-
cokinase activity was calculated as the difference between the glucose
phosphorylation capacity at 100 and 0.5 mmol/L glucose. Protein content was
measured by Bradford assay (Pointe Scientiﬁc) and glucokinase activity was
expressed as mU/mg of protein.
Insulin sensitivity test in mice. Awake, fed AAV1-oGck– or AAV1-null–
treated diabetic mice were intraperitoneally injected with 0.75 IU/kg body
weight of insulin (Humulin regular; Eli Lilly). Glucose concentration was de-
termined in blood samples obtained from tail vein before and at 0, 15, 30, 45,
and 60 min after the insulin injection.
Statistical analysis. All values are expressed as means 6 SEM. Differences
between groups were compared by unpaired Student t test. P , 0.05 was
considered statistically signiﬁcant.
RESULTS
Glycemic control by insulin alone. After experimental
diabetes induction, three dogs (DogDb1–3) were subjected
to glycemic control with subcutaneous exogenous insulin
according to hormone administration regimens and feed-
ing protocols indicated for diabetic companion dogs. De-
spite therapy, fasting normoglycemia was not achieved in
any of the animals (Fig. 1A–C); one of the animals,
DogDb3, experienced severe fasting hyperglycemia. Ex-
ogenous insulin therapy prevented weight loss in all dogs
(Fig. 1A–C). All these animals showed elevated fructos-
amine levels (Fig. 2A), a marker of glycosylated proteins in
blood and an indicator of recent (3 weeks) glycemic con-
trol used in veterinary medicine (19–21). Finally, diabetic
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FIG. 1. Glycemic control by exogenous insulin. A–D: Follow-up of fasting glycemia and body weight of diabetic control dogs (DogDb1–4) treated
daily with exogenous insulin (dosage [IU] and timing [24 h vs. 12 h] are shown). DogDb1, square; DogDb2, diamond; DogDb3, circle; DogDb4,
triangle. Db, dog treatment with streptozotocin (STZ) plus alloxan. A indicates the period of adjustment of the insulin dosing regimen. Gray bar
indicates fasting normoglycemia range in dogs (20).
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dogs showed a marked and sustained increase in blood
glucose compared with healthy animals when sub-
jected to an OGTT at the American Diabetes Association–
recommended standard dose of glucose (1.75 g/kg) (22)
(Fig. 2B).
In an effort to further improve glycemic control, a new
treatment regimen with exogenous insulin was estab-
lished. In DogDb1 and DogDb2, and in an additional di-
abetic dog (DogDb4), insulin dosing was increased as
much as possible without causing severe hypoglycemia;
this was performed on an individual basis with twice-daily
administrations. In addition, dogs were fed with diabetic
food distributed in two servings. Despite treatment opti-
mization, no major changes were observed in fasted gly-
cemia (Fig. 1A, B, D), whereas the improvement in
glycemic control resulted in lower fructosamine levels,
which decreased to below the upper limit of good glycemic
control (Fig. 2A) in veterinary medicine (450 mmol/L) (19–
21) and improved OGTT (Fig. 2B).
When insulin alone was expressed in skeletal muscle of
a diabetic dog by administration of 13 1012 vg/kg of AAV1-
Ins vector (DogIns), partial correction of fasting glycemia
was achieved (Fig. 3A). This animal recovered the body
weight initially lost after diabetes induction and had fruc-
tosamine levels that ranged between 250 and 300 mmol/L
after gene transfer (Fig. 3B, C). Despite achieving normal
levels of fasting insulinemia (Fig. 3D), the ability of DogIns
to dispose of glucose after an OGTT was only moderately
improved compared with diabetic dogs (Fig. 3E).
Ins and Gck gene transfer to skeletal muscle corrects
diabetes in dogs. Five diabetic dogs (Dog1–4 and
DogDb3+Ins/Gck) were intramuscularly administered with
AAV1-Ins and AAV1-Gck vectors. Administration of 1 3 1012
vg/kg of each vector to Dog1 and Dog2 resulted in rapid
return to fasting normoglycemia and normoinsulinemia,
recovery of body weight (Fig. 4A, B, and Video 2), and long-
term survival (.4 years, observation ongoing). The admin-
istration of a twice-high vector dose (23 1012 vg/kg) of each
vector to Dog3 was also safe and resulted in correction of
diabetes with no episodes of hypoglycemia (Fig. 4C, D).
Thus, Ins and Gck gene transfer results in better control
of diabetes than exogenous insulin therapy or gene
transfer for Ins only. This result was further conﬁrmed in
DogDb3 (Fig. 1C), which was treated with AAV1-Ins and
FIG. 2. Fructosamine levels and glucose disposal after a load in dogs treated with exogenous insulin. A: Monitoring of serum fructosamine in
DogDb1–4 receiving exogenous insulin every 24 or 12 h. The fructosamine upper limit for good diabetes control in dogs is indicated with the dashed
line. Fructosamine concentrations between 350 and 400 mmol/L indicate excellent glycemic control, concentrations between 400 and 450 mmol/L
indicate good glycemic control, concentrations between 450 and 500 mmol/L indicate fair glycemic control, and concentrations >500 mmol/L in-
dicate poor glycemic control (20). Results are shown as mean 6 SEM of 2–4 determinations. B: OGTTs were performed at 1.75 g/kg glucose before
(healthy) and after diabetes induction in DogDb1–3 treated with exogenous insulin every 24 h (left) or in DogDb1, DogDb2, and DogDb4 receiving
insulin every 12 h (right). Mean 6 SEM, n = 3. (A high-quality color representation of this ﬁgure is available in the online issue.)
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AAV1-Gck after 5 months of poorly controlled glycemia
(now named DogDb3+Ins/Gck), resulting in normalization
of glycemia without exogenous insulin administration.
Codon-optimized versions of human transgenes also were
tested to achieve better glycemic control at doses of 1 3
1012 vg/kg, because use of codon-optimized genes
increases the production of proteins (23). Delivery of
AAV1-oIns and AAV1-oGck to Dog4 led to rapid recovery
of normoglycemia, normoinsulinemia, and body weight
(Fig. 4E), with no signs of fasting hypoglycemia detected
during the 5-month follow up.
In all Ins- and Gck-treated dogs, fructosamine levels
remained within the range of 250–350 mmol/L (Fig. 5A).
When an OGTT was performed at a dose of 1.75 g/kg,
treated dogs showed only a small increase in glycemia
after the load, followed by return to normoglycemia within
2 hours, a proﬁle considered nondiabetic by American
Diabetes Association guidelines (2-h plasma glucose ,200
mg/dL) (22), with the exception of DogDb3+Ins/Gck,
which was ;200 mg/dL at 120 min (Fig. 5B). Furthermore,
Ins- and Gck-treated dogs showed improved glucose dis-
posal even after high-dose (3 g/kg) glucose load; peak
glycemia was lower than that of diabetic dogs and 2-h
glycemia declined to ,200 mg/dL (Supplementary Fig. 2).
Importantly, Dogs1–4 and DogDb3+Ins/Gck showed good
glycemic control with exercise, with no development of
hypoglycemia (Fig. 6). In agreement with normalization
of glycemia, ketone bodies were never detected in the
urine of these dogs (data not shown). Finally, Ins- and
Gck-treated dogs did not show signs of secondary
complications, whereas DogDb1–3 developed cataracts
a few months after hyperglycemia development (Sup-
plementary Table 2).
Both transgenes were expressed in skeletal muscle (Fig.
7A), and glucokinase was active in this tissue (Fig. 7B).
Circulating insulin in AAV1-treated dogs derived from ex-
pression of Ins transgene in muscle, as documented by the
lack of surviving b cells in pancreas biopsy samples (Fig.
7A, C, D) and with the detection of human C-peptide in
serum (Fig. 7E). In contrast to healthy dogs, and in
agreement with the lack of pancreatic insulin-producing
cells, the ﬁrst phase peak of insulin release after a meal
was not observed in AAV1-treated dogs (Fig. 7F). To-
gether, these ﬁndings suggest that circulating insulin
detected in AAV1-treated dogs derives from the expression
of the Ins transgene in skeletal muscle and not from re-
sidual expression from surviving b cells. All AAV1-Ins
+Gck–treated diabetic dogs showed normal circulating
glucagon levels (Fig. 7G), indicating preservation of a-cell
function.
FIG. 3. Glycemic control by AAV1-Ins alone. Diabetic dog treated with AAV1-Ins (1 3 1012 vg/kg; DogIns) showed partial normalization of fasting
blood glucose levels (A) and recovery of body weight loss (B). C: Fructosamine monitoring in DogIns. Results are shown as mean 6 SEM of more
than four measurements per year. D: Fasting insulinemia of DogIns. Dashed lines indicate average maximum and minimum fasting insulinemia
values obtained by random measurements in six healthy dogs. E: No major improvement was observed in the ability of DogIns to dispose of glucose
during an OGTT at 1.75 g/kg performed 4 years after gene transfer when compared with diabetic dogs under optimized exogenous insulin treat-
ment. Db indicates dog treatment with streptozotocin (STZ) plus alloxan. Gray bar indicates fasting normoglycemia range in dogs (20). DogIns,
diamond symbols in panels A, B, and D.
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FIG. 4. Treatment with AAV1-Ins and AAV1-Gck corrects diabetes in dogs. A–D: Follow-up of glycemia, body weight, and insulinemia. Five diabetic
dogs (Dog1–4 and DogDb3+Ins/Gck) were treated with AAV1-Ins and AAV1-Gck vectors at 1 3 1012 vg/kg each for Dog1 and Dog2 (A and B), at 2 3
1012 vg/kg each for Dog3 and DogDb3+Ins/Gck (C and D), or with AAV1-oIns and AAV1-oGck vectors at 1 3 1012 vg/kg each for Dog4 (E). Dogs had
serum insulin levels that remained within the range of fasted healthy animals (dashed lines). Db indicates dog treatment with streptozotocin (STZ)
plus alloxan. Gray bars indicate fasting normoglycemia range in dogs (20).
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The production of insulin in skeletal muscle increased the
phosphorylated AKT/total AKT ratio in muscle ﬁbers, in-
dicating that insulin activated its signaling in an autocrine/
paracrine manner (Supplementary Fig. 3). Also, in agree-
ment with the absence of glucokinase regulatory protein
in skeletal muscle (data not shown) (24), glucokinase
was detected only in the cytosol of AAV1-treated muscle
ﬁbers, even after a glucose challenge (Supplementary
Fig. 4).
Dog3 was euthanized at 2.2 years after gene transfer,
and vector genome biodistribution analysis conﬁrmed
that most of the detectable vector was present in injec-
ted muscles (Supplementary Table 3). Normal muscle
morphology without glycogenosis was documented in
AAV1-injected animals (Supplementary Fig. 5 and Sup-
plementary Table 4).
Role of the glucokinase transgene in glycemic control.
Two diabetic dogs were treated with AAV1-oGck vectors
alone at 2 3 1012 vg/kg (DogGck1 and DogGck2). After
vector delivery, both dogs remained hyperglycemic and
required administration of exogenous insulin to reduce
hyperglycemia and to stabilize weight loss (Fig. 8A, B),
demonstrating that glucokinase expression alone is not
sufﬁcient to counteract hyperglycemia. Consistently, fruc-
tosamine was elevated in both dogs (Fig. 8C) and they
developed cataracts a few months after hyperglycemia
development (Supplementary Table 2). Dogs expressing
glucokinase alone showed an impaired OGTT (1.75 g/kg),
with glycemia curves similar to those of diabetic non-
treated animals (Fig. 8D).
Similar to what it was performed with diabetic control
dogs, exogenous insulin treatment was optimized on an
individual basis in DogGck1 and DogGck2 with twice-daily
administrations. Although no decline in fasted glycemia or
fructosamine levels was observed (Fig. 8A–C), an im-
provement in OGTT was documented (Fig. 8D).
The higher sensitivity to exogenous insulin of DogsGck
was, however, evidenced when an OGTT was performed
with simultaneous subcutaneous injection of insulin.
DogGck1 and DogGck2 had a faster glucose disposal
than diabetic control dogs, with glycemia declining to
,200 mg/dL in both animals (Fig. 8E). Increased sensi-
tivity to exogenous insulin was also observed in diabetic
mice treated with AAV1-oGck (Supplementary Fig. 6).
DISCUSSION
Since the 1922 breakthrough discovery of Banting and
Best, who corrected hyperglycemia in dogs using pancre-
atic extracts, exogenous insulin administration has been the
mainstay of diabetes therapy. Alternative therapies have
been studied, but thus far only a few approaches, mainly
involving allotransplantation or xenotransplantation of
pancreatic islets, have reached clinical application (2).
FIG. 5. AAV1-Ins and AAV1-Gck treatment normalizes serum fructos-
amine and recovers glucose disposal after a load. A: Dog1–4 and
DogDb3+Ins/Gck had levels of serum fructosamine that ranged from
200 to 350 mmol/L. B: OGTT at a dose of glucose of 1.75 g/kg. Ins- and
Gck-treated dogs showed a glucose proﬁle similar to healthy animals
and below the range for diabetes diagnosis according to American Di-
abetes Association guidelines (2-h plasma glucose <200 mg/dL). Data
are represented as mean 6 SEM of 2–3 OGTTs performed every year or
during the study period in dogs with shorter follow-up. OGTTs for di-
abetic control dogs (red line) were performed during the period of in-
tensive exogenous insulin treatment.
FIG. 6. Effect of exercise on glycemia. Blood glucose was measured in
24-h fasted dogs before, immediately after exercise, and during post-
exercise recovery. None of the dogs was hypoglycemic over the periods
analyzed. Dog1–4 and DogDb3+Ins/Gck showed good glycemic control
under exercise, comparable with that of healthy dogs. A decline in blood
glucose was observed after exercise in dogs treated with AAV1-Ins or
with AAV1-oGck vectors only; these dogs had baseline glucose levels
much higher than those of all other animals treated with AAV1-Ins and
AAV1-Gck vectors.
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FIG. 7. Skeletal muscle is the source of insulin after AAV1-Ins and AAV1-Gck treatment. A: Transgene expression in skeletal muscle of AAV1-
treated dogs. Northern blot analysis showing expression of insulin and glucokinase in skeletal muscle biopsy specimens from DogIns and Dog1, and
necropsy samples from Dog3, obtained 9 months and 2.2 years after treatment, respectively. Uninjected muscle was used as a control. B: Mea-
surement of glucokinase activity in skeletal muscle of healthy (H) dog and two different necropsy samples from Dog3. C: The b-cell area was
quantiﬁed in necropsy samples (whole pancreas) from a healthy dog, a diabetic dog, and Dog3 (2.2 years after treatment), and in pancreas biopsy
samples from Dog1, Dog2, and DogIns obtained 9 months after AAV1 administration. Diabetes induction led to>90% reduction in b-cell mass in all
dogs. D: Representative images of pancreatic sections stained with insulin (red) and glucagon (green) illustrating the marked reduction of insulin-
producing cells in Dog3 by 2.2 years after diabetes induction. Original magniﬁcation 2003. E: Human C-peptide was detectable in serum of all
AAV1-Ins–treated dogs, but not in healthy (H) or untreated diabetic (Db) dogs, indicating that proinsulin was produced and processed in skeletal
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In the clinical translation of bench results, the scale-up to
a large animal model represents perhaps one of the most
critical steps. This was demonstrated by the work per-
formed in gene transfer for hemophilia B (12,25–27) and
Leber congenital amaurosis (13,28), in which results for
dogs were fully predictive of the outcome in humans.
Our novel approach to control hyperglycemia, through
genetic engineering of a “glucose sensor” in skeletal mus-
cle using AAV1 vectors, has permitted long-term, clinically
meaningful regulation of glycemia in a large animal model
of diabetes. Currently, the goal of normalization of glyce-
mia is pursued through intensive insulin therapy, which
can delay the onset and slow the progression of secondary
complications of diabetes (1). However, this treatment is
not suitable for all diabetic patients because of its high risk
of hypoglycemia secondary to excessive insulin dosage
(1). Additionally, cell therapies, including cadaveric and
stem cell–derived islet transplantation, require life-long
immunosuppression (2,29). Our approach circumvents
a number of the challenges of diabetes therapy. In contrast
to allotransplantation, in which supplies of human pan-
creatic islets are limiting, AAV vector manufacturing is
robust and unlimited. Moreover, long-term (.10 years)
transgene expression has been documented in humans
after AAV vector administration to skeletal muscle (30).
The intramuscular delivery of AAV1 vectors to engineer
the skeletal muscle results in expression of both trans-
genes in the target tissue, and not in the liver, the other
tissue where vector genomes are detected, probably be-
cause of the silencing of the cytomegalovirus promoter
(31). Our results support a model in which the production
of insulin in skeletal muscle activates insulin signaling in
an autocrine/paracrine manner, and the constant insulin
production deriving from AAV1-Ins–transduced ﬁbers is
crucial for the system to work as a glucose sensor. Low
basal levels of insulin are required to keep muscle ca-
pable of uptaking glucose by ensuring continuous GLUT4
translocation to the plasmatic membrane (9). Thus, glu-
cose transport does not become a rate-limiting step to the
system before a glucose challenge. However, because of
the absence of glucokinase regulatory protein in muscle,
the glucokinase produced in this tissue through gene
transfer remains active in the cytosol (24). As a result, in
a situation of hyperglycemia, glucokinase phosphorylates
glucose efﬁciently, driving the uptake of large amounts of
glucose through GLUT4 into the engineered muscle ﬁbers.
Then, AAV1-Ins alone is able to maintain good control of
fasted glycemia, but AAV1-Gck is required to cope with
a glucose overload, as shown by the OGTTs. The advan-
tage of expressing both genes in the same muscle cell
would be that by acting in an autocrine/paracrine manner,
the levels of insulin required to achieve sufﬁcient GLUT4
expression in the muscle ﬁber are low and therefore safe.
Regarding the systemic action of insulin derived from the
skeletal muscle, we have previously demonstrated that
transgenic mice expressing insulin and glucokinase under
the control of a muscle-speciﬁc promoter or diabetic mice
treated with AAV1-Ins+Gck gene transfer have restored
glucokinase and markedly reduced PEPCK expression in
the liver (9). PEPCK is the most important enzyme in the
control of gluconeogenesis and is regulated mainly at
transcriptional level, with its expression upregulated in
starvation or diabetes (32). This evidence suggests that
hepatic gluconeogenesis is reduced in Ins- and Gck-
treated diabetic animals when compared with untreated
diabetic controls, which would contribute to better gly-
cemic control.
Insulin alone, either provided as exogenous therapy or
expressed in muscle by an AAV1 vector, did induce glu-
cose uptake; however, it did not guarantee tight control of
glycemia, especially after a glucose challenge. Expression
of glucokinase alone did not correct hyperglycemia either.
Diabetic dogs treated with high doses of AAV1-Gck were
hyperglycemic in fasting conditions. However, expression
of glucokinase in muscle results in greater sensitivity to
insulin, either when insulin is exogenously administered or
when it is expressed at low, safe levels from an AAV1
vector. Furthermore, even if an intensive exogenous in-
sulin treatment is adjusted on an individual basis for each
diabetic control or AAV1-Gck–treated dog, the glycemic
control achieved by Ins and Gck gene therapy is superior,
as evidenced by the lower fasted glycemia and fructos-
amine levels, and improved glucose disposal in AAV1-
Ins+Gck–treated animals. Thus, only the synergistic action
of insulin and glucokinase allows for tight control of di-
abetic hyperglycemia.
Skeletal muscle has a number of key advantages as
a target tissue for AAV-mediated gene transfer. Muscle is
easily accessible by noninvasive procedures, and vector
delivery leads to minimal systemic biodistribution (Sup-
plementary Table 2). Moreover, gene delivery to muscle is
not limited by the presence of preexisting neutralizing
antibodies against AAV (33), a key aspect given the rela-
tively high prevalence of anti-AAV antibodies in the gen-
eral population (34). In addition, muscle has a metabolism
highly based on glucose consumption and can efﬁciently
secrete proteins into the bloodstream. Insulin can be pro-
duced, processed, and secreted as a mature protein from
skeletal muscle, provided the gene has a genetic modiﬁ-
cation allowing the cleavage by the endoprotease furin (9).
We have been unable to detect insulin within muscle ﬁbers
of transgenic or AAV1-treated mice, suggesting that the
insulin produced in muscle ﬁbers is not accumulated in
vesicles and that its secretion is unlikely to be regulated by
vesicle-mediated exocytosis (as in pancreatic b cells). In
contrast, secretion from the skeletal muscle seems to be
constitutive.
Long-term follow-up of treated dogs suggests that mus-
cle expression of insulin and glucokinase is well-tolerated
over a prolonged period. Studies conﬁrmed the safety of
the approach even under marked physical exertion, when
high levels of glucose consumption increase the risk of
hypoglycemic episodes. The use of a large animal model
with a long life span allowed us to follow-up animals for
early indicators of secondary complications. The absence
of clinical ﬁndings, such as cataracts or urinary tract in-
fection, and the reduction of biomarkers, such as glyco-
sylated proteins (fructosamine), suggest that Ins and Gck
gene transfer may prevent diabetes complications. Hence,
normalization of glycemia with a one-time intervention
muscle. Results are shown as mean 6 SEM (n = 23–56 measurements per dog). F: Time course of insulin secretion after a meal 4 years after AAV1
treatment of Dog1, Dog2, and DogIns. Basal levels correspond to a 24-h fasting period, after which animals were fed a 30-g/kg serving of standard
diet. Only the healthy dogs showed the ﬁrst peak of insulin release, which corresponds to pancreatic secretion of the insulin stored in secretory
granules. G: Normal circulating glucagon levels were observed in AAV1-Ins– and AAV1-Gck–treated dogs indicating preservation of a-cell function.
Results are shown as mean 6 SEM (n = 5–6 measurements per dog). H, healthy; Db, diabetic; Con, control; ND, nondetected.
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FIG. 8. Diabetic dogs treated with AAV1-oGck alone. Follow-up of glycemia and body weight of diabetic dogs treated with AAV1-oGck vectors
(2 3 1012 vg/kg) in DogGck1 (A) and DogGck2 (B). DogGck remained hyperglycemic during fast and required daily administration of exogenous
insulin (dosage [IU] and timing [24 h vs. 12 h] are shown). C: Fructosamine levels were altered in DogGck1 and DogGck2 receiving exogenous
insulin every 24 or 12 h. Results are shown as mean 6 SEM of 2–4 determinations. D: DogGck1 and DogGck2 showed similar OGTT proﬁles at 1.75
g/kg as diabetic untreated dogs when administered with exogenous insulin once daily. On implementation of the optimized treatment, OGTT
improved. E: The synergistic effect of glucokinase and insulin. DogGck1 and DogGck2 and diabetic control dogs were administered a glucose load
(1.75 g/kg) together with a subcutaneous injection of insulin (6 IU). Data are represented as mean 6 SEM of 3 OGTTs. Db indicates dog treatment
with streptozotocin (STZ) plus alloxan. Gray bars indicate fasting normoglycemia range in dogs (20).
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could result in a substantial improvement in patient quality
of life, particularly in populations with difﬁculties in di-
abetes management, such as brittle diabetes (35).
One possible limitation of the results presented here is
that the dog model of diabetes used in this study does not
fully mimic the immunological state of type 1 diabetic
patients. However, although future studies in autoimmune
models of diabetes are warranted, studies of mice (36),
dogs (37), and humans (38) would suggest that targeting
muscle with AAV vectors may at least partially escape
immune recognition. This may be the result of lower levels
of major histocompatibility complex class I presentation in
this tissue, or the result of the induction of apoptosis of
reactive T cells (36,38).
In summary, our data represent the ﬁrst demonstration
of long-term correction of diabetes in a large animal model
using gene transfer. Future safety and efﬁcacy studies will
help to determine the range of Ins and Gck vector doses
that are therapeutic, as well as the glucokinase/insulin
expression ratio that is optimal for a tight control of gly-
cemia. These studies will provide the basis for the initia-
tion of a clinical veterinary study in companion animals
with diabetes, a strategy also proposed for the clinical
development of cancer therapeutics (39). The proposed
clinical trial of diabetic dogs that are pets will greatly help
deﬁne the safety and efﬁcacy proﬁles of our approach in
humans. One added advantage of this strategy is also re-
lated to the fact that large experimental animal models of
autoimmune diabetes do not exist; thus, companion ani-
mals with naturally occurring diabetes constitute an ex-
tremely valuable and stringent model. In conclusion, this
study lays the foundation for the clinical translation of this
approach to veterinary medicine and possibly to humans.
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